Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 156-163

  Aebi, Stefan ^a,b,c   Gelber, Shari ^d,e   Anderson, Stewart J ^f   Láng, István ^h   Robidoux, André ⁱ   Martín, Miguel ^j   Nortier, Johan W R ^k   Paterson, Alexander H G ^l   Rimawi, Mothaffar F ^m   Cañada, José Manuel Baena ⁿ   Thürlimann, Beat ^c,o   Murray, Elizabeth ^p   Mamounas, Eleftherios P ^q   Geyer, Charles E ^r   Price, Karen N ^d,e   Coates, Alan S ^s,t   Gelber, Richard D ^d,e   Rastogi, Priya ^g   Wolmark, Norman ^u   Wapnir, Irene L ^v  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l TOM BAKER CANCER CENTRE   (Canada)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^o Breast Center   (Switzerland)

^p UNIVERSITY OF CAPE TOWN   (South Africa)

^q M D ANDERSON CANCER CENTER ORLANDO   (United States)

^r VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^s International Breast Cancer Study Group   (Switzerland)

^t UNIVERSITY OF SYDNEY   (Australia)

^u ALLEGHENY GENERAL HOSPITAL   (United States)

^v STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE INFECTION; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; NEUTROPENIA; PARTIAL MASTECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SOUTH AFRICA; SOUTH AMERICA; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84892973397     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70589-8     Document Type: Article

References (28)

1. Clemons M, Danson S, Hamilton T, Goss P Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 2001, 27:67-82.
2. Haffty BG, Fischer D, Beinfield M, McKhann C Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991, 21:293-298.
3. Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993, 11:44-48.
4. Whelan T, Clark R, Roberts R, Levine M, Foster G Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Int J Radiat Oncol Biol Phys 1994, 30:11-16. Investigators of the Ontario Clinical Oncology Group.
5. Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 1996, 14:52-57.
6. Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1999, 43:25-38.
7. Freedman GM, Fowble BL Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Huntingt) 2000, 14:1561-1581.
8. Schwaibold F, Fowble BL, Solin LJ, Schultz DJ, Goodman RL The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991, 21:299-310.
9. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 2006, 24:2028-2037.
10. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009, 27:2466-2473.
11. Wapnir IL, Aebi S, Geyer CE, et al. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer 2008, 8:287-292.
12. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
13. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
14. Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003, 14:1215-1221.
15. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
16. Kaplan EL, Meier P Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958, 53:457-481.
17. Cox DR Regression models and life-tables (with discussion). J R Stat Soc B (Methodology) 1972, 34:187-220.
18. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
19. Rauschecker H, Clarke M, Gatzemeier W, Recht A Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev 2001, 4. CD002195.
20. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
21. Freedman B Equipoise and the ethics of clinical research. N Engl J Med 1987, 317:141-145.
22. Clemons M, Hamilton T, Mansi J, Lockwood G, Goss P Management of recurrent locoregional breast cancer: oncologist survey. Breast 2003, 12:328-337.
23. Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011, 22:2227-2233.
24. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 2012, 23(suppl):x349-x353.
25. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010, 12:R75.
26. Hoefnagel LD, Moelans CB, Meijer SL Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012, 118:4929-4935.
27. Gan HK, You B, Pond GR, Chen EX Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Nat Cancer Inst 2012, 104:590-598.
28. Christley RM Power and error: increased risk of false positive results in underpowered studies. Open Epidemiol J 2010, 3:16-19.